TABLE 2.
Characteristics of patients enrolled in key CAR‐T cell therapy clinical trials
| Patient characteristics | ZUMA‐1 4 , 5 (N = 101) a | JULIET 2 , 10 (N = 115) | TRANSCEND 6 , 12 (N = 269) |
|---|---|---|---|
| Median age, years (range) | 58 (23–76) | 56 (22–76) | 63 (18–86) |
| Patients ≥65 years, % | 24 | 23 | 42 |
| HGBCL/double/triple hit, % | 6 | 17 | 13 |
| Stage III/IV, % | 85 | 76 | – |
| ECOG PS, % | |||
| 0–1 | 100 | 100 | 99 |
| 2+ | 0 | 0 | 1 |
| Refractory to last line of therapy, % | 98 b , c | 55 | 67 c |
| Previous autoSCT, % | 21 | 49 | 33 |
| Previous lines of therapy, median (range) | 3 (IQR 2–4) | 3 (1–6) | 3 (1–8) |
| 1 line, % | 3 | 5 | – |
| 2 lines, % | 28 | 44 | – |
| ≥3 lines, % | 69 | 51 | – |
| ≥4 lines, % | – | 20 | 26 |
| Received bridging therapy, % | 0 | 90 | 59 |
Note: The purpose of this table is to summarize data. Head‐to‐head studies have not been performed and no comparisons can be made.
Abbreviations: autoSCT, autologous stem cell transplant; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; HGBCL, high grade B‐cell lymphoma; IQR, inter quartile range.
‐ refers to not reported.
a
Phase 2 cohort.
b
Refractory to second‐line or later; 2% were primary refractory.
c
Relapsed < 12 months after autoSCT.